Search

Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis with a worldwide incidence of approximately 0.7-1.2 million cases per year, and 90% of these cases are in Asia, the Middle East, South America, and North Africa.[1] CL prevalence normally increases with age up to around 15 years, after which time prevalence levels off, likely due to immunity acquisition.[2] Pentavalent antimony medications are still the most effective treatment for leishmaniasis, however, because of the severe side effects and the need for parenteral administration, other therapies such as oral medicines for CL have been sought.[3] Given the extended duration of the illness and the disfiguring impact of unhealed skin lesions, a well-tolerated oral medication would be beneficial. No drug discontinuation or any case drop out was noted as the drug was well tolerated and there was noticeable improvement in clinical response. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. [Extracted from the article]